Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -54%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Orum Therapeutics
A475830 · KOSDAQ₩44,600+17.99%
2026-08-03 closeLoading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p
Beat the market on 62.1% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 6.01
Distress
Grey
Safe
- Altman Z''
- 6.01
- Beneish M-Score
- —
- Sloan accrual
- 3.60%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
0/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score0/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROANot passed
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -39.9%
- Interest coverage
- -4.6x
- Return on equity (ROE)
- -4.7%
Operating margin −5pp
Operating lossInterest coverageBase -4.6x adverse case -5.2x
Return on equity (ROE)Base -4.7% adverse case -9.2%
Revenue −15%
Interest coverage riskInterest coverageBase -4.6x adverse case -4x
Return on equity (ROE)Base -4.7% adverse case -7.3%
Interest rate +2pp
Interest coverage riskInterest coverageBase -4.6x adverse case -3.4x
Return on equity (ROE)Base -4.7% adverse case -8.8%
Interest coverage limit
Already below the limit by 48.5ppInterest coverage limit at an operating margin of 8.6%
Interest expense coverage threshold
Financials at a glance
Orum Therapeutics's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 이승주15.85%2026-06-09 · 증감 -0.26%p
Connections
AI-extracted related companies · for reference
Competitors
Same theme
Recent filings
Orum Therapeutics's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy